Increased serum levels of miR‑214 in patients with PCa with bone metastasis may serve as a potential biomarker by targeting PTEN

Fang,Yi; Qiu,Jun; Jiang,Zong‑Bin; Xu,Sheng‑Rong; Zhou,Zeng‑Hua; He,Rui‑Lin

doi:10.3892/ol.2018.9522

Increased serum levels of miR‑214 in patients with PCa with bone metastasis may serve as a potential biomarker by targeting PTEN

Authors:
- Yi Fang
- Jun Qiu
- Zong‑Bin Jiang
- Sheng‑Rong Xu
- Zeng‑Hua Zhou
- Rui‑Lin He
View Affiliations

Affiliations: Department of Anesthesiology, Changsha Central Hospital, Changsha, Hunan 410000, P.R. China, Oncology Department Two, Mawangdui Hospital of Hunan People's Hospital, Changsha, Hunan 410016, P.R. China, Department of Pain Medicine, Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530000, P.R. China
Published online on: September 28, 2018 https://doi.org/10.3892/ol.2018.9522
Pages: 398-405

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs/miRs) are identified to serve key functions in the progression of various tumors. miR-214 is aberrantly expressed in various types of cancer. In the present study, the function of miR‑214 and its feasibility as a potential non‑invasive biomarker for patients with prostate cancer (PCa) in a hyperplasia group and a control group were investigated. First, RNA was isolated from the serum of 75 patients with PCa with bone metastasis, 65 patients with PCa with no bone metastasis and 70 healthy controls. The level of miR‑214 expression was significantly upregulated in the serum of the bone metastasis group compared with the healthy control and non‑bone metastasis groups. Expression levels of alkaline phosphatase (ALP), bone sialoprotein (BSP), collagen type I pyridine crosslinking peptide (ICTP) were also evaluated. The results indicated that serum levels of BSP, ALP and ICTP were increased in the bone metastasis group compared with that in the non‑bone metastasis group, hyperplasia group and the control group (P<0.05). The expression level of miR‑214 is positively associated with poorly differentiated tumors in patients with PCa with a Gleason score >7 (P<0.05). Western blot analysis demonstrated that phosphatase and tensin homolog (PTEN) was a target gene of miR‑214. Additionally, silencing of PTEN significantly increased the invasive ability of PC3 cells even when miR‑214 expression was inhibited. In summary, serum miR‑214 expression may serve as a potential novel non‑invasive biomarker for PCa screening through targeting PTEN.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Fedewa SA, Miller KD, Goding-Sauer A, Pinheiro PS, Martinez-Tyson D and Jemal A: Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin. 65:457–480. 2015. View Article : Google Scholar : PubMed/NCBI
3	Luna A, Vilanova JC and Alcalá Mata L: Total body MRI in early detection of bone metastasis and its indication in comparison to bone scan and other imaging techniques. Arch Esp Urol. 68:371–390. 2015.(In Spanish). PubMed/NCBI
4	Ramankulov A, Lein M, Kristiansen G, Loening SA and Jung K: Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate. 67:330–340. 2007. View Article : Google Scholar : PubMed/NCBI
5	Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E and de Koning H: Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context. J Natl Cancer Inst. 101:374–383. 2009. View Article : Google Scholar : PubMed/NCBI
6	Kim EH and Andriole GL: Prostate-specific antigen-based screening: Controversy and guidelines. BMC Med. 13:612015. View Article : Google Scholar : PubMed/NCBI
7	Kitagawa Y and Namiki M: Prostate-specific antigen-based population screening for prostate cancer: Current status in Japan and future perspective in Asia. Asian J Androl. 17:475–480. 2015.PubMed/NCBI
8	Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE, Takahashi N and Kawashima A: Detection of recurrent prostate cancer after radical prostatectomy: Comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med. 55:223–232. 2014. View Article : Google Scholar : PubMed/NCBI
9	ChunJiao S, Huan C, ChaoYang X and GuoMei R: Uncovering the roles of miRNAs and their relationship with androgen receptor in prostate cancer. IUBMB Life. 66:379–386. 2014. View Article : Google Scholar : PubMed/NCBI
10	Pekarik V, Gumulec J, Masarik M, Kizek R and Adam V: Prostate cancer, miRNAs, metallothioneins and resistance to cytostatic drugs. Curr Med Chem. 20:534–544. 2013. View Article : Google Scholar : PubMed/NCBI
11	Stuopelytė K, Daniūnaitė K, Jankevičius F and Jarmalaitė S: Detection of miRNAs in urine of prostate cancer patients. Medicina (Kaunas). 52:116–124. 2016. View Article : Google Scholar : PubMed/NCBI
12	Sun T, McKay R, Lee GS and Kantoff P: The role of miRNAs in prostate cancer. Eur Urol. 68:589–590. 2015. View Article : Google Scholar : PubMed/NCBI
13	Chang YS, Chen WY, Yin JJ, Sheppard-Tillman H, Huang J and Liu YN: EGF receptor promotes prostate cancer bone metastasis by downregulating miR-1 and activating TWIST1. Cancer Res. 75:3077–3086. 2015. View Article : Google Scholar : PubMed/NCBI
14	Chen WY, Liu SY, Chang YS, Yin JJ, Yeh HL, Mouhieddine TH, Hadadeh O, Abou-Kheir W and Liu YN: MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer. Oncotarget. 6:441–457. 2015.PubMed/NCBI
15	Xin R, Bai F, Feng Y, Jiu M, Liu X, Bai F, Nie Y and Fan D: MicroRNA-214 promotes peritoneal metastasis through regulating PTEN negatively in gastric cancer. Clin Res Hepatol Gastroenterol. 40:748–754. 2016. View Article : Google Scholar : PubMed/NCBI
16	Kuninty PR, Bojmar L, Tjomsland V, Larsson M, Storm G, Östman A, Sandström P and Prakash J: MicroRNA-199a and −214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor. Oncotarget. 7:16396–16408. 2016. View Article : Google Scholar : PubMed/NCBI
17	Das F, Dey N, Bera A, Kasinath BS, Ghosh-Choudhury N and Choudhury GG: MicroRNA-214 reduces insulin-like growth factor-1 (IGF-1) receptor expression and downstream mTORC1 signaling in renal carcinoma cells. J Biol Chem. 291:14662–14676. 2016. View Article : Google Scholar : PubMed/NCBI
18	Tang SL, Gao YL and and Chen XB: MicroRNA-214 targets PCBP2 to suppress the proliferation and growth of glioma cells. Int J Clin Exp Pathol. 8:12571–12576. 2015.PubMed/NCBI
19	Siemińska L, Borowski A, Marek B, Nowak M, Kajdaniuk D, Warakomski J and Kos-Kudła B: Serum concentrations of adipokines in men with prostate cancer and benign prostate hyperplasia. Endokrynol Pol. Feb 21–2018.(Epub ahead of print).
20	Jansson UH, Kristiansson B, Magnusson P, Larsson L, Albertsson-Wikland K and Bjarnason R: The decrease of IGF-I, IGF-binding protein-3 and bone alkaline phosphatase isoforms during gluten challenge correlates with small intestinal inflammation in children with coeliac disease. Eur J Endocrinol. 144:417–423. 2001. View Article : Google Scholar : PubMed/NCBI
21	Ofori JK, Salunkhe VA, Bagge A, Vishnu N, Nagao M, Mulder H, Wollheim CB, Eliasson L and Esguerra JL: Elevated miR-130a/miR130b/miR-152 expression reduces intracellular ATP levels in the pancreatic beta cell. Sci Rep. 7:449862017. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Zou ZJ, Fan L, Wang L, Xu J, Zhang R, Tian T, Li JY and Xu W: miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation. Oncotarget. 6:1276–1285. 2015. View Article : Google Scholar : PubMed/NCBI
24	Yang TS, Yang XH, Wang XD, Wang YL, Zhou B and Song ZS: MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN. Cancer Cell Int. 13:682013. View Article : Google Scholar : PubMed/NCBI
25	Fujii T, Shimada K, Tatsumi Y, Fujimoto K and Konishi N: Syndecan-1 responsive microRNA-126 and 149 regulate cell proliferation in prostate cancer. Biochem Biophys Res Commun. 456:183–189. 2015. View Article : Google Scholar : PubMed/NCBI
26	Fu H, He HC, Han ZD, Wan YP, Luo HW, Huang YQ, Cai C, Liang YX, Dai QS, Jiang FN and Zhong WD: MicroRNA-224 and its target CAMKK2 synergistically influence tumor progression and patient prognosis in prostate cancer. Tumour Biol. 36:1983–1991. 2015. View Article : Google Scholar : PubMed/NCBI
27	Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
28	Ha TY: MicroRNAs in human diseases: From cancer to cardiovascular disease. Immune Netw. 11:135–154. 2011. View Article : Google Scholar : PubMed/NCBI
29	Baranwal S and Alahari SK: miRNA control of tumor cell invasion and metastasis. Int J Cancer. 126:1283–1290. 2010.PubMed/NCBI
30	Liu B, Tian Y, Li F, Zhao Z, Jiang X, Zhai C, Han X and Zhang L: Tumor-suppressing roles of miR-214 and miR-218 in breast cancer. Oncol Rep. 35:3178–3184. 2016. View Article : Google Scholar : PubMed/NCBI
31	Chen BF, Suen YK, Gu S, Li L and Chan WY: A miR-199a/miR-214 self-regulatory network via PSMD10, TP53 and DNMT1 in testicular germ cell tumor. Sci Rep. 4:64132014. View Article : Google Scholar : PubMed/NCBI
32	Yin Y, Cai X, Chen X, Liang H, Zhang Y, Li J, Wang Z, Chen X, Zhang W, Yokoyama S, et al: Tumor-secreted miR-214 induces regulatory T cells: A major link between immune evasion and tumor growth. Cell Res. 24:1164–1180. 2014. View Article : Google Scholar : PubMed/NCBI
33	Jindra PT, Bagley J, Godwin JG and Iacomini J: Costimulation-dependent expression of microRNA-214 increases the ability of T cells to proliferate by targeting Pten. J Immunol. 185:990–997. 2010. View Article : Google Scholar : PubMed/NCBI
34	Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, Oermann EK, Uhm S, Kim JS, Chen LN, et al: MicroRNA profiling in prostate cancer-the diagnostic potential of urinary miR-205 and miR-214. PLoS One. 8:e769942013. View Article : Google Scholar : PubMed/NCBI
35	Kamiya N, Suzuki H, Yano M, Endo T, Takano M, Komaru A, Kawamura K, Sekita N, Imamoto T and Ichikawa T: Implications of serum bone turnover markers in prostate cancer patients with bone metastasis. Urology. 75:1446–1451. 2010. View Article : Google Scholar : PubMed/NCBI
36	Moslehi M, Cheki M, Salehi-Marzijarani M, Amuchastegui T and Gholamrezanezhad A: Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naive patients with prostate cancer. Rev Esp Med Nucl Imagen Mol. 32:286–289. 2013.PubMed/NCBI